TELIX PHARMACEUTICALS LIMITED news, videos and press releases - Page 2
For more news please use our advanced search feature.
TELIX PHARMACEUTICALS LIMITED - More news...
TELIX PHARMACEUTICALS LIMITED - More news...
- Telix Submits NDA for New Prostate Cancer Imaging Agent
- Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
- Telix Files Registration Statement for Proposed Initial Public Offering in the United States
- Q1 2024 Revenue and Business Update
- Q1 2024 Revenue and Business Update
- TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
- World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
- QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
- QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
- QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy
- Appointment of Dr Darren Patti to Group Chief Operating Officer
- Appointment of Dr Darren Patti to Group Chief Operating Officer
- Appointment of Dr Darren Patti to Group Chief Operating Officer
- Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
- Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
- Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
- Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
- Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
- Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
- Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
- Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
- Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
- Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
- Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
- Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
- Telix Announces Planned Registered Public Offering and Listing in the United States
- Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
- First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent
- Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
